Helps diagnose suspected or known acute opioid overdosage. ANDA 70172, held by Hospira. Naloxone Hydrochloride.
As of Nov 22, 2026, ANDA 70172 (Naloxone Hydrochloride), held by Hospira, was first approved by FDA on Apr 18, 1986, with 6 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see INDICATIONS & USAGE: Adjunctive Use in Septic Shock).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Naloxone Hydrochloride0.4MG/ML · injectable;injection | Naloxone Hydrochloride | Rx |
| May 31, 2023 | Supplement 31Labeling · Standard review | Approved | None posted |
| Feb 23, 2004 | Supplement 6Labeling | Approved | None posted |
| Feb 14, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Dec 22, 1995 | Supplement 3Manufacturing | Approved | None posted |
| Apr 26, 1993 | Supplement 2Manufacturing | Approved | None posted |
| Nov 19, 1992 | Supplement 1Labeling | Approved | None posted |
| Apr 18, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters